Abstract
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use may be associated with less well known, but sometimes clinically relevant, adverse effects. More specifically, the use of orlistat has been associated with several mild-to-moderate gastrointestinal adverse effects, such as oily stools, diarrhoea, abdominal pain and faecal spotting. A few cases of serious hepatic adverse effects (cholelithiasis, cholostatic hepatitis and subacute liver failure) have been reported. However, the effects of orlistat on non-alcoholic fatty liver disease are beneficial. Orlistat-induced weight loss seems to have beneficial effects on blood pressure. No effect has been observed on calcium, phosphorus, magnesium, iron, copper or zinc balance or on bone biomarkers. Interestingly, the use of orlistat has been associated with rare cases of acute kidney injury, possibly due to the increased fat malabsorption resulting from the inhibition of pancreatic and gastric lipase by orlistat, leading to the formation of soaps with calcium and resulting in increased free oxalate absorption and enteric hyperoxaluria. Orlistat has a beneficial effect on carbohydrate metabolism. No significant effect on cancer risk has been reported with orlistat.
Orlistat interferes with the absorption of many drugs (such as warfarin, amiodarone, ciclosporin and thyroxine as well as fat-soluble vitamins), affecting their bioavailability and effectiveness.
This review considers orlistat-related adverse effects and drug interactions. The clinical relevance and pathogenesis of these effects is also discussed.
Similar content being viewed by others
References
Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007 Feb; 63(2): 205–9
Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001 Jul; 281(1): G16–28
Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997 Jun; 21 Suppl. 3: S12–23
Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994 Jul; 56(1): 82–5
Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35(11): 1103–8
Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996 Nov; 36(11): 1006–11
Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39(1): 41–6
US Food and Drug Administration. FDA approves orlistat for over-the-counter use [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/new01557.html [Accessed 2007 Oct 15]
Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005 Nov; 7(6): 699–708
Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27(1): 155–61
Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4(6): 415–23
Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and Cardiovascular risk profile in patients with metabolic 62 syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004 Sep; 20(9): 1393–401
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999 Jan 20; 281(3): 235–42
Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 Jun 15; 293(23): 2873–83
O’Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004 Feb; 5(1): 51–68
O’Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5(18): 1–81
Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352(9123): 167–72
Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998 Apr; 54(2): 125–32
Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003 Dec; 27(12): 1437–46
Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract]. 16th International Diabetes Federation Congress; 1997 Jul 25–27, Helsinki
Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005 Feb; 31(1): 15–22
Napier S, Thomas M. 36 year old man presenting with pancreatitis and a history of recent commencement of orlistat: case report. NutrJ 2006; 5: 19
Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996 Dec; 41(12): 2404–8
Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007 Jan; 30(1): 27–32
Kim DH, Lee EH, Hwang JC, et al. A case of acute cholestatic hepatitis associated with orlistat [in Korean] [abstract]. Taehan Kan Hakhoe Chi 2002 Sep; 8(3): 317–20
Montero JL, Muntane J, Fraga E, et al. Orlistat associated subacute hepatic failure. J Hepatol 2001 Jan; 34(1): 173
Thurairajah PH, Syn WK, Neil DA, et al. Orlistat (Xenical)-induced subacute liver failure. Eur J Gastroenterol Hepatol 2005 Dec; 17(12): 1437–8
Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by orlistat? Med Sci Law 2002 Oct; 42(4): 309–12
Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med 2006 Aug; 119(8): e7
Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007 Feb; 42(2): 139–47
Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006 May; 22(5): 873–83
Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004 Sep 15; 20(6): 623–8
Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of _yclosporine_ fatty liver disease. Clin Gastroenterol Hepatol 2006 May; 4(5): 639–44
Caner M, Dogruman H, Taskin E, et al. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. Chin J Physiol 2005 Dec 31; 48(4): 217–22
O’Donovan D, Horowitz M, Russo A, et al. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 2004 Dec; 47(12): 2208–14
Pilichiewicz A, O’Donovan D, Feinle C, et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 2003 Aug; 88(8): 3829–34
Goedecke JH, Barsdorf M, Beglinger C, et al. Effects of a lipase inhibitor (orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord 2003 Dec; 27(12): 1479–85
Fox M, Thumshirn M, Menne D, et al. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. Aliment Pharmacol Ther 2004 Feb 1; 19(3): 311–21
Heck AM, Calis KA, McDuffie JR, et al. Additive gastrointestinal effects with concomitant use of olestra and orlistat. Ann Pharmacother 2002 Jun; 36(6): 1003–5
Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001 Jul; 25(7): 1095–9
Fox M, Stutz B, Menne D, et al. The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Dig Dis Sci 2005 Sep; 50(9): 1576–83
Guarino AH. Treatment of intractable constipation with orlistat: a report of three cases. Pain Med 2005 Jul–Aug; 6(4): 327–8
Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002 Sep; 20(9): 1873–8
Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005 Jan; 7(1): 47–55
Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20(11): 2257–67
Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004 May; 8(21): iii–iv, 1–182
Zavoral JH.Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens. 1998 Dec; 16 (12 Pt 2): 2013–7
Schneider R, Golzman B, Turkot S, et al. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005 Oct; 330(4): 157–60 63
Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A (2) in obese patients with metabolic syndrome. Atherosclerosis 2007; 193(2): 428–37
Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005 Dec; 21(12): 1997–2006
Zanella MT, Uehara MH, Ribeiro AB, et al. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol 2006 Apr; 50(2): 368–76
Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001 Apr 1; 87(7): 827–31
Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 May; 5(3): 180–8
Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21(8): 1288–94
Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 Sep; 56(7): 494–9
Derosa G, Cicero AF, Murdolo G, et al. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004 Aug; 17(4): 222–9
Bloch KV, Salles GF, Muxfeldt ES, et al. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens 2003 Nov; 21(11): 2159–65
Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002 Nov 25; 162(21): 2428–35
Kuo CS, Pei D, Yao CY, et al. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2006 Aug; 60(8): 906–10
Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005 Mar; 21(3): 457–68
Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007 Jan 6; 369(9555): 71–7
Persson M, Vitols S, Yue QY. Orlistat associated with hypertension [letter]. BMJ 2000 Jul 8; 321(7253): 87
Johnston GD. Orlistat associated with hypertension: digit preference lays conclusions about orlistat open to doubt [letter]. BMJ 2001 Jan 13; 322(7278): 110
Huber MH. Orlistat associated with hypertension: Roche concludes that there is not evidence of a casual association. BMJ 2001 Jan 13; 322(7278): 110–1
Patten SB. Major depressive episodes and diet pills. Expert Opin Pharmacother 2002 Oct; 3(10): 1405–9
Benazzi F. Depression induced by orlistat (Xenical) [letter]. Can J Psychiatry 2000 Feb; 45(1): 87
Kiortsis DN, Tsouli S, Filippatos TD, et al. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomized study. Nutr Metab Cardiovasc Dis. In press
Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005 Oct; 13(10): 1701–8
heleritis CG, Papadimitriou GN, Papageorgiou CC, et al. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC Psychiatry 2006; 6: 37
Fernandez-Aranda F, Amor A, Jimenez-Murcia S, et al. Bulimia nervosa and misuse of orlistat: two case reports. Int J Eat Disord 2001 Dec; 30(4): 458–61
Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004 Dec; 58(10): 582–7
Acharya NV, Wilton LV, Shakir SA. Safety profile of orlistat: results of a prescription-event monitoring study. Int J Obes 2006; 30: 1645–52
Pritchard JE, Nowson CA, Wark JD. Bone loss accompanying diet-induced or exercise-induced weight loss: a randomised controlled study. Int J Obes Relat Metab Disord 1996 Jun; 20(6): 513–20
Pace DG, Blotner S, Guerciolini R. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr 2001 Jun; 131(6): 1694–9
Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003 Oct; 22(5): 357–62
Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001 Aug; 25(8): 1154–60
Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int 2004 Aug; 66(2): 676–82
Singh A, Sarkar SR, Gaber LW, et al. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007 Jan; 49(1): 153–7
Courtney AE, O’Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007 Feb; 22(2): 621–3
Packard KA, Wurdeman RL, Reyes AP. Constipation, polyuria, polydipsia, and edema associated with orlistat. Ann Pharmacother 2002 Jul–Aug; 36(7–8): 1168–70
Rowe R, Cowx M, Poole C, et al. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 2005 Nov; 21(11): 1885–90
Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006 Feb; 7(2): 211–28
Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005 May; 22(5): 612–8
Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25(7): 1123–8 64
Xenical® (orlistat) capsules [prescribing information]. Revised 2003 Dec. Roche Laboratories Inc. [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2003/03DEC_PI/Xenical_PI.pdf [Accessed 2007 Oct 15]
Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003 Jun; 26(6): 1667–72
Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007 Jan; 66(1): 103–9
Diamanti-Kandarakis E, Piperi C, Alexandraki K, et al. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 2006 Apr; 55(4): 494–500
Czerwienska B, Kokot F, Franek E, et al. Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects [in Polish]. Pol Arch Med Wewn 2004 Dec; 112(6): 1415–23
Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006 Jun; 7(6): 761–71
Jayagopal V, Kilpatrick ES, Holding S, et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005 Feb; 90(2): 729–33
Damci T, Yalin S, Balci H, et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004 May; 27(5): 1077–80
Azar ST, Zantout MS. Diabetic ketoacidosis associated with orlistat treatment [letter]. Diabetes Care 2001 Mar; 24(3): 602
Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, et al. Orlistat-induced cutaneous leukocytoclastic vasculitis [letter]. Arthritis Rheum 2002 Oct 15; 47(5): 567
Sergeant A, Milne G, Shaffrali F. Lichenoid eruption associated with orlistat. Br J Dermatol 2006 May; 154(5): 1020–1
Morotomi M, Sakaitani Y, Satou M, et al. Effects of a high-fat diet on azoxymethane-induced aberrant crypt foci and fecal biochemistry and microbial activity in rats. Nutr Cancer 1997; 27(1): 84–91
Newmark HL, Yang K, Lipkin M, et al. A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. Carcinogenesis 2001 Nov; 22(11): 1871–5
Thornton Jr WH, MacDonald RS. Dietary fat quantity and composition induce changes in proliferation and membrane lipids in rat colon cells. Ann Nutr Metab 1997; 41(4): 260–8
Garcia SB, Barros LT, Turatti A, et al. The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett 2006 Aug 28; 240(2): 221–4
Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004 Mar 15; 64(6): 2070–5
Menendez JA, Vellon L, Lupu R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood) 2005 Mar; 230(3): 151–4
Browne CD, Hindmarsh EJ, Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 2006 Oct; 20(12): 2027–35
Menendez JA, Vellon L, Lupu R. The antiobesity drug orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer 2006 Jan–Feb; 16(1): 219–21
Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005 Aug; 16(8): 1253–67
Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN): catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 2006 Dec; 7(6): 483–93
Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36(7): 647–53
Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996 Feb; 36(2): 152–9
McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 Jul; 22(7): 814–22
Holecki M, Zahorska-Markiewicz B, Nieszporek T, et al. The influence of a 3-month weight reduction therapy with orlistat on serum vitamin B12 and folic acid concentration in obese women. Int J Obes (Lond) 2006 Jun; 30(6): 1017–8
Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36(7): 659–66
MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003 Apr; 37(4): 510–2
Zhi J, Moore R, Kanitra L, et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003 Apr; 43(4): 428–35
Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000 Nov 27; 70(10): 1541–2
Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporine-neoral and orlistat. Am J Kidney Dis 2003 Feb; 41(2): 493–6
Nagele H, Petersen B, Bonacker U, et al. Effect of orlistat on blood cyclosporine concentration in an obese heart transplant patient. Eur J Clin Pharmacol 1999 Nov; 55(9): 667–9
Asberg A. Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63(4): 367–78
Barbaro D, Orsini P, Pallini S, et al. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002 Mar–Apr; 8(2): 124–6
Schnetzler B, Kondo-Oestreicher M, Vala D, et al. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation 2000 Nov 27; 70(10): 1540–1
Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 Sep; 42(9): 1011–9
Errasti P, Garcia I, Lavilla J, et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc 2002 Feb; 34(1): 137–9 65
Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med 2000 Apr 13; 342(15): 1141–2
Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat [letter]. Epilepsia 2006 Dec; 47(12): 2207
Hilger E, Quiner S, Ginzel I, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002 Feb; 22(1): 68–70
Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain [letter]. Eur Psychiatry 2005 Nov; 20(7): 520
Peleg R. Caution when using oral contraceptive pills with Orlistat [letter]. Isr Med Assoc J 2000 Sep; 2(9): 712
Hartmann D, Guzelhan C, Zuiderwijk PB, et al. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50(5): 421–4
Madhava K, Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine [letter]. Clin Oncol (R Coll Radiol) 2005 Sep; 17(6): 492
Chaikomin R, Russo A, Rayner CK, et al. Effects of lipase inhibition on gastric emptying and alcohol absorption in healthy subjects. Br J Nutr 2006 Nov; 96(5): 883–7
Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998 Nov–Dec; 54(9–10): 773–7
Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25(6): 1033–41
Pathan MF, Latif ZA, Nazneen NE, et al. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Med Res Counc Bull 2004 Apr; 30(1): 1–8
Sari R, Balci MK, Coban E, et al. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004 Aug; 28(8): 1059–63
Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995 May; 35(5): 521–5
Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36(7): 654–8
Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996; 51(1): 87–90
Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36(4): 352–5
Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003 Apr; 25(4): 1107–22
Acknowledgements
No sources of funding were used to assist in the preparation of this review. Some of the authors have given talks, attended conferences and participated in trials and advisory boards sponsored by various pharmaceutical companies including Roche.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Filippatos, T.D., Derdemezis, C.S., Gazi, I.F. et al. Orlistat-Associated Adverse Effects and Drug Interactions. Drug-Safety 31, 53–65 (2008). https://doi.org/10.2165/00002018-200831010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200831010-00005